Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Influenza, Human | 61 | 2013 | 329 | 5.440 |
Why?
|
Polymorphism, Single Nucleotide | 83 | 2014 | 2356 | 4.380 |
Why?
|
Genetic Predisposition to Disease | 81 | 2014 | 2270 | 3.960 |
Why?
|
Genetic Linkage | 69 | 2012 | 623 | 3.870 |
Why?
|
Genome-Wide Association Study | 59 | 2014 | 1620 | 3.450 |
Why?
|
Influenza A virus | 43 | 2013 | 169 | 3.280 |
Why?
|
Diabetes Mellitus, Type 2 | 68 | 2013 | 1373 | 3.230 |
Why?
|
Influenza Vaccines | 26 | 2012 | 142 | 2.730 |
Why?
|
Influenza A Virus, H5N1 Subtype | 22 | 2011 | 63 | 2.620 |
Why?
|
Genetic Variation | 44 | 2014 | 1351 | 2.570 |
Why?
|
Influenza A Virus, H3N2 Subtype | 22 | 2013 | 80 | 2.360 |
Why?
|
Influenza A Virus, H1N1 Subtype | 21 | 2013 | 102 | 2.170 |
Why?
|
Calpain | 20 | 2006 | 111 | 2.150 |
Why?
|
Chromosome Mapping | 58 | 2013 | 1074 | 2.110 |
Why?
|
Pharmacogenetics | 18 | 2014 | 434 | 1.900 |
Why?
|
Models, Genetic | 34 | 2014 | 926 | 1.800 |
Why?
|
Disease Outbreaks | 16 | 2013 | 154 | 1.690 |
Why?
|
Quantitative Trait Loci | 21 | 2013 | 576 | 1.690 |
Why?
|
Polymorphism, Genetic | 41 | 2014 | 819 | 1.640 |
Why?
|
Genome, Human | 34 | 2014 | 756 | 1.630 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 19 | 2011 | 70 | 1.620 |
Why?
|
Humans | 350 | 2014 | 86601 | 1.460 |
Why?
|
Genotype | 56 | 2013 | 1850 | 1.420 |
Why?
|
Linkage Disequilibrium | 26 | 2013 | 473 | 1.130 |
Why?
|
Reassortant Viruses | 9 | 2011 | 23 | 1.120 |
Why?
|
Computational Biology | 15 | 2014 | 528 | 1.100 |
Why?
|
Alleles | 37 | 2013 | 1127 | 1.090 |
Why?
|
Influenza in Birds | 11 | 2013 | 31 | 1.090 |
Why?
|
Pedigree | 43 | 2011 | 966 | 1.020 |
Why?
|
Diabetes Mellitus, Type 1 | 12 | 2013 | 567 | 1.010 |
Why?
|
Insulin | 19 | 2009 | 1160 | 0.990 |
Why?
|
Chromosomes, Human, Pair 15 | 7 | 2010 | 63 | 0.960 |
Why?
|
Haplotypes | 29 | 2011 | 642 | 0.930 |
Why?
|
Female | 159 | 2014 | 44507 | 0.920 |
Why?
|
Antibodies, Viral | 14 | 2011 | 293 | 0.920 |
Why?
|
Chromosomes, Human, Pair 6 | 8 | 2013 | 125 | 0.920 |
Why?
|
Obsessive-Compulsive Disorder | 6 | 2013 | 157 | 0.900 |
Why?
|
Stuttering | 10 | 2006 | 22 | 0.900 |
Why?
|
Gene Frequency | 30 | 2013 | 677 | 0.890 |
Why?
|
Phenotype | 37 | 2014 | 2377 | 0.880 |
Why?
|
Chromosomes, Human, Pair 11 | 7 | 2006 | 106 | 0.880 |
Why?
|
Genomics | 10 | 2014 | 720 | 0.830 |
Why?
|
Male | 136 | 2014 | 40956 | 0.820 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2014 | 592 | 0.800 |
Why?
|
Gene Expression Profiling | 15 | 2014 | 1384 | 0.770 |
Why?
|
Asthma | 14 | 2014 | 955 | 0.770 |
Why?
|
Antineoplastic Agents | 11 | 2014 | 2357 | 0.730 |
Why?
|
Autistic Disorder | 5 | 2009 | 147 | 0.720 |
Why?
|
Quantitative Trait, Heritable | 9 | 2013 | 124 | 0.720 |
Why?
|
Orthomyxoviridae Infections | 8 | 2013 | 46 | 0.710 |
Why?
|
Case-Control Studies | 25 | 2014 | 1804 | 0.710 |
Why?
|
Lod Score | 17 | 2007 | 152 | 0.700 |
Why?
|
Epistasis, Genetic | 4 | 2010 | 86 | 0.700 |
Why?
|
MicroRNAs | 6 | 2014 | 534 | 0.670 |
Why?
|
Chromosomes, Human, Pair 2 | 11 | 2010 | 85 | 0.670 |
Why?
|
Polycystic Ovary Syndrome | 7 | 2009 | 203 | 0.670 |
Why?
|
Nerve Tissue Proteins | 7 | 2012 | 503 | 0.650 |
Why?
|
Cell Line | 23 | 2014 | 2468 | 0.650 |
Why?
|
Genetic Markers | 30 | 2007 | 476 | 0.630 |
Why?
|
Antiviral Agents | 12 | 2010 | 510 | 0.620 |
Why?
|
Polymorphism, Restriction Fragment Length | 21 | 2005 | 147 | 0.620 |
Why?
|
Oligonucleotide Array Sequence Analysis | 12 | 2011 | 689 | 0.620 |
Why?
|
Gene Expression Regulation | 12 | 2014 | 1920 | 0.620 |
Why?
|
Polymerase Chain Reaction | 12 | 2011 | 927 | 0.620 |
Why?
|
Child | 55 | 2014 | 6926 | 0.610 |
Why?
|
Receptors, Virus | 5 | 2011 | 74 | 0.610 |
Why?
|
Obesity | 9 | 2010 | 963 | 0.610 |
Why?
|
Molecular Sequence Data | 39 | 2011 | 3030 | 0.600 |
Why?
|
Databases, Genetic | 8 | 2012 | 260 | 0.590 |
Why?
|
Gene Dosage | 4 | 2011 | 207 | 0.590 |
Why?
|
Adult | 89 | 2013 | 25640 | 0.590 |
Why?
|
Transcriptome | 5 | 2014 | 580 | 0.570 |
Why?
|
Tourette Syndrome | 2 | 2013 | 25 | 0.560 |
Why?
|
Islets of Langerhans | 8 | 2006 | 544 | 0.550 |
Why?
|
Base Sequence | 32 | 2011 | 2330 | 0.550 |
Why?
|
Ferrets | 13 | 2013 | 47 | 0.540 |
Why?
|
Genes, Viral | 12 | 2008 | 116 | 0.530 |
Why?
|
Neuraminidase | 10 | 2012 | 45 | 0.520 |
Why?
|
Adolescent | 49 | 2013 | 8979 | 0.510 |
Why?
|
ATP-Binding Cassette Transporters | 6 | 2014 | 141 | 0.510 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2006 | 85 | 0.500 |
Why?
|
Genes | 3 | 2011 | 305 | 0.490 |
Why?
|
Breast Neoplasms | 10 | 2014 | 2887 | 0.480 |
Why?
|
Receptors, Drug | 5 | 2007 | 54 | 0.470 |
Why?
|
Alternative Splicing | 4 | 2012 | 201 | 0.470 |
Why?
|
Mexican Americans | 10 | 2013 | 63 | 0.470 |
Why?
|
Influenza A Virus, H2N2 Subtype | 4 | 2011 | 10 | 0.460 |
Why?
|
Orthomyxoviridae | 5 | 2013 | 37 | 0.460 |
Why?
|
Nucleoproteins | 4 | 2011 | 21 | 0.460 |
Why?
|
Disease | 2 | 2013 | 90 | 0.460 |
Why?
|
Virus Replication | 10 | 2012 | 319 | 0.460 |
Why?
|
Influenza B virus | 7 | 2010 | 29 | 0.460 |
Why?
|
Algorithms | 9 | 2014 | 1830 | 0.450 |
Why?
|
Multifactorial Inheritance | 4 | 2014 | 158 | 0.450 |
Why?
|
Animals | 57 | 2013 | 26581 | 0.450 |
Why?
|
Genetic Diseases, Inborn | 5 | 2011 | 101 | 0.450 |
Why?
|
Gene Expression | 7 | 2012 | 1284 | 0.450 |
Why?
|
Exons | 6 | 2012 | 450 | 0.450 |
Why?
|
Bipolar Disorder | 7 | 2012 | 377 | 0.440 |
Why?
|
Middle Aged | 63 | 2014 | 25017 | 0.440 |
Why?
|
Potassium Channels, Inwardly Rectifying | 5 | 2007 | 119 | 0.440 |
Why?
|
Child, Preschool | 33 | 2013 | 3611 | 0.440 |
Why?
|
Fibrillar Collagens | 1 | 2012 | 10 | 0.440 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2013 | 52 | 0.440 |
Why?
|
Blood Glucose | 8 | 2013 | 873 | 0.440 |
Why?
|
Pandemics | 3 | 2011 | 740 | 0.440 |
Why?
|
Software | 12 | 2014 | 654 | 0.440 |
Why?
|
Potassium Channels | 6 | 2007 | 340 | 0.430 |
Why?
|
Drug Resistance, Viral | 7 | 2012 | 51 | 0.420 |
Why?
|
Tamoxifen | 2 | 2013 | 168 | 0.420 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2014 | 1197 | 0.410 |
Why?
|
Seasons | 9 | 2013 | 223 | 0.410 |
Why?
|
Receptors, GABA-A | 2 | 2009 | 32 | 0.410 |
Why?
|
HSP40 Heat-Shock Proteins | 1 | 2011 | 18 | 0.400 |
Why?
|
Amino Acid Sequence | 22 | 2011 | 2062 | 0.400 |
Why?
|
eIF-2 Kinase | 1 | 2011 | 46 | 0.400 |
Why?
|
Mutation, Missense | 6 | 2011 | 276 | 0.400 |
Why?
|
Vaccination | 6 | 2009 | 254 | 0.400 |
Why?
|
Virology | 1 | 2011 | 9 | 0.390 |
Why?
|
Carboplatin | 6 | 2011 | 286 | 0.390 |
Why?
|
Cell Proliferation | 4 | 2012 | 1578 | 0.390 |
Why?
|
Population Groups | 1 | 2010 | 41 | 0.390 |
Why?
|
Hyperglycemia | 3 | 2012 | 176 | 0.380 |
Why?
|
Influenza A Virus, H9N2 Subtype | 3 | 2003 | 8 | 0.380 |
Why?
|
Communicable Disease Control | 1 | 2011 | 51 | 0.380 |
Why?
|
Virus Attachment | 1 | 2010 | 6 | 0.380 |
Why?
|
Diabetic Retinopathy | 2 | 2012 | 87 | 0.380 |
Why?
|
Phosphoproteins | 4 | 2009 | 254 | 0.380 |
Why?
|
Leukocytes | 2 | 2014 | 202 | 0.370 |
Why?
|
DNA | 12 | 2010 | 1294 | 0.370 |
Why?
|
Genetic Testing | 8 | 2012 | 535 | 0.370 |
Why?
|
Sex Factors | 9 | 2011 | 1054 | 0.370 |
Why?
|
United States | 30 | 2013 | 6665 | 0.370 |
Why?
|
Cisplatin | 5 | 2013 | 612 | 0.370 |
Why?
|
Antigens, Viral | 8 | 2008 | 143 | 0.370 |
Why?
|
Biostatistics | 1 | 2010 | 20 | 0.360 |
Why?
|
Germ-Line Mutation | 5 | 2012 | 329 | 0.360 |
Why?
|
Infant | 22 | 2013 | 3045 | 0.360 |
Why?
|
Models, Statistical | 4 | 2012 | 574 | 0.360 |
Why?
|
Diabetes Mellitus | 4 | 2007 | 806 | 0.350 |
Why?
|
Population Surveillance | 5 | 2012 | 219 | 0.350 |
Why?
|
Hemagglutinins, Viral | 9 | 2000 | 38 | 0.350 |
Why?
|
Neoplasms | 7 | 2014 | 2897 | 0.350 |
Why?
|
Warfarin | 3 | 2013 | 103 | 0.350 |
Why?
|
Cell Line, Tumor | 12 | 2014 | 2426 | 0.350 |
Why?
|
Disease Susceptibility | 10 | 2011 | 193 | 0.340 |
Why?
|
Chickens | 4 | 2011 | 212 | 0.340 |
Why?
|
Virus Internalization | 1 | 2009 | 39 | 0.340 |
Why?
|
Platinum | 2 | 2014 | 63 | 0.340 |
Why?
|
Aged | 39 | 2013 | 18402 | 0.340 |
Why?
|
Hemagglutination Inhibition Tests | 10 | 2009 | 37 | 0.330 |
Why?
|
Founder Effect | 7 | 2001 | 104 | 0.330 |
Why?
|
RNA, Viral | 12 | 2009 | 327 | 0.330 |
Why?
|
Pregnancy Complications | 3 | 2012 | 336 | 0.320 |
Why?
|
Cohort Studies | 17 | 2014 | 2767 | 0.320 |
Why?
|
Immunization Schedule | 2 | 2009 | 21 | 0.320 |
Why?
|
Hyperinsulinism | 2 | 2010 | 51 | 0.310 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2012 | 375 | 0.310 |
Why?
|
Chromosomes, Human, Pair 20 | 4 | 2004 | 32 | 0.310 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 44 | 0.310 |
Why?
|
Liver | 6 | 2013 | 1229 | 0.300 |
Why?
|
Psychiatry | 2 | 2008 | 78 | 0.300 |
Why?
|
Coronary Stenosis | 1 | 2007 | 39 | 0.300 |
Why?
|
Day Care, Medical | 4 | 1999 | 11 | 0.300 |
Why?
|
Pancreas | 2 | 2010 | 239 | 0.300 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 76 | 0.300 |
Why?
|
Phylogeny | 12 | 2012 | 1137 | 0.290 |
Why?
|
Drug Discovery | 2 | 2012 | 103 | 0.290 |
Why?
|
Anticoagulants | 3 | 2013 | 408 | 0.290 |
Why?
|
Diabetes Complications | 4 | 2012 | 207 | 0.290 |
Why?
|
Adamantane | 3 | 2008 | 8 | 0.290 |
Why?
|
Risk | 9 | 2012 | 674 | 0.290 |
Why?
|
Mutation | 19 | 2011 | 3967 | 0.290 |
Why?
|
Abdominal Fat | 1 | 2006 | 13 | 0.280 |
Why?
|
Family | 7 | 2005 | 311 | 0.280 |
Why?
|
Systems Biology | 2 | 2014 | 42 | 0.280 |
Why?
|
Swine | 6 | 2013 | 555 | 0.280 |
Why?
|
Coronary Angiography | 1 | 2007 | 232 | 0.280 |
Why?
|
Mice, Inbred BALB C | 11 | 2013 | 1047 | 0.280 |
Why?
|
Membrane Transport Proteins | 4 | 2009 | 166 | 0.280 |
Why?
|
Cholesterol | 2 | 2003 | 356 | 0.270 |
Why?
|
Insulin Resistance | 5 | 2012 | 377 | 0.270 |
Why?
|
Transcription Factors | 8 | 2012 | 1565 | 0.270 |
Why?
|
Biomarkers, Tumor | 3 | 2014 | 1464 | 0.270 |
Why?
|
Glucuronosyltransferase | 2 | 2012 | 184 | 0.270 |
Why?
|
Research Design | 8 | 2012 | 594 | 0.260 |
Why?
|
Amino Acid Substitution | 7 | 2011 | 339 | 0.260 |
Why?
|
Body Mass Index | 9 | 2013 | 770 | 0.260 |
Why?
|
Leucine | 2 | 2003 | 67 | 0.260 |
Why?
|
Neuroblastoma | 2 | 2014 | 374 | 0.260 |
Why?
|
Chromosomes, Human, Pair 3 | 2 | 2013 | 54 | 0.260 |
Why?
|
Vaccines, Attenuated | 6 | 2011 | 51 | 0.260 |
Why?
|
Schizophrenia | 2 | 2006 | 464 | 0.260 |
Why?
|
Membrane Glycoproteins | 4 | 2009 | 428 | 0.260 |
Why?
|
Molecular Epidemiology | 3 | 2011 | 53 | 0.250 |
Why?
|
Hong Kong | 12 | 2007 | 45 | 0.250 |
Why?
|
Computer Simulation | 9 | 2012 | 1078 | 0.250 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2010 | 109 | 0.250 |
Why?
|
Tandem Mass Spectrometry | 2 | 2011 | 103 | 0.250 |
Why?
|
Pancreatitis | 2 | 1997 | 87 | 0.250 |
Why?
|
Chick Embryo | 5 | 2010 | 229 | 0.250 |
Why?
|
HLA Antigens | 6 | 2004 | 232 | 0.240 |
Why?
|
Signal Transduction | 6 | 2013 | 3241 | 0.240 |
Why?
|
Japan | 10 | 2006 | 307 | 0.240 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2013 | 27 | 0.240 |
Why?
|
Genetic Loci | 3 | 2013 | 250 | 0.240 |
Why?
|
Hyperlipidemia, Familial Combined | 1 | 2003 | 5 | 0.240 |
Why?
|
Risk Factors | 20 | 2012 | 5416 | 0.240 |
Why?
|
Meta-Analysis as Topic | 3 | 2012 | 87 | 0.240 |
Why?
|
Chromosomes, Human, Pair 1 | 4 | 2007 | 100 | 0.230 |
Why?
|
Therapeutics | 1 | 2013 | 12 | 0.230 |
Why?
|
Estrogen Antagonists | 1 | 2013 | 48 | 0.230 |
Why?
|
Linear Models | 5 | 2013 | 421 | 0.230 |
Why?
|
Femoral Neck Fractures | 1 | 2013 | 11 | 0.230 |
Why?
|
Vitamin K | 1 | 2013 | 25 | 0.230 |
Why?
|
Sulfonylurea Receptors | 5 | 2007 | 50 | 0.230 |
Why?
|
Influenza A Virus, H7N3 Subtype | 1 | 2013 | 3 | 0.230 |
Why?
|
Viral Tropism | 1 | 2013 | 4 | 0.230 |
Why?
|
Conjunctivitis | 1 | 2013 | 6 | 0.230 |
Why?
|
Chromosomes, Artificial, Yeast | 5 | 1996 | 37 | 0.230 |
Why?
|
Genome, Viral | 5 | 2009 | 74 | 0.230 |
Why?
|
Hearing Loss | 1 | 2013 | 56 | 0.230 |
Why?
|
Antifibrinolytic Agents | 1 | 2013 | 30 | 0.230 |
Why?
|
Catechol O-Methyltransferase | 1 | 2013 | 68 | 0.230 |
Why?
|
Respiratory Mucosa | 3 | 2013 | 88 | 0.230 |
Why?
|
DNA Copy Number Variations | 2 | 2011 | 171 | 0.230 |
Why?
|
Pregnancy | 12 | 2013 | 2893 | 0.220 |
Why?
|
Mental Disorders | 3 | 2008 | 371 | 0.220 |
Why?
|
Attitude of Health Personnel | 2 | 2008 | 636 | 0.220 |
Why?
|
Triglycerides | 1 | 2003 | 232 | 0.220 |
Why?
|
Glucose Tolerance Test | 7 | 2013 | 228 | 0.220 |
Why?
|
Protein Interaction Maps | 1 | 2013 | 48 | 0.220 |
Why?
|
Likelihood Functions | 8 | 2006 | 251 | 0.220 |
Why?
|
Reproducibility of Results | 8 | 2014 | 2705 | 0.220 |
Why?
|
Data Interpretation, Statistical | 6 | 2007 | 297 | 0.220 |
Why?
|
Mixed Function Oxygenases | 2 | 2013 | 68 | 0.220 |
Why?
|
Universities | 1 | 2013 | 135 | 0.220 |
Why?
|
Vaccines, Inactivated | 6 | 2011 | 29 | 0.220 |
Why?
|
Methyltransferases | 1 | 2013 | 182 | 0.220 |
Why?
|
Privacy | 1 | 2012 | 20 | 0.210 |
Why?
|
Nitriles | 1 | 2012 | 149 | 0.210 |
Why?
|
Hypersensitivity, Immediate | 3 | 2004 | 62 | 0.210 |
Why?
|
Postmenopause | 1 | 2012 | 98 | 0.210 |
Why?
|
Young Adult | 13 | 2013 | 5974 | 0.210 |
Why?
|
Temperature | 3 | 2013 | 396 | 0.210 |
Why?
|
Time Factors | 11 | 2014 | 5209 | 0.210 |
Why?
|
Cross Protection | 1 | 2011 | 8 | 0.210 |
Why?
|
Triazoles | 1 | 2012 | 96 | 0.210 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2006 | 51 | 0.210 |
Why?
|
Sample Size | 1 | 2012 | 130 | 0.210 |
Why?
|
DNA Primers | 11 | 2002 | 543 | 0.210 |
Why?
|
Macular Edema | 1 | 2012 | 50 | 0.210 |
Why?
|
Sequence Analysis, DNA | 6 | 2011 | 853 | 0.210 |
Why?
|
Leukemia, Myeloid | 2 | 2009 | 249 | 0.200 |
Why?
|
Microtubule-Associated Proteins | 1 | 2012 | 176 | 0.200 |
Why?
|
Ducks | 3 | 2009 | 8 | 0.200 |
Why?
|
Glutathione Transferase | 2 | 2008 | 111 | 0.200 |
Why?
|
Epithelial Cells | 3 | 2013 | 669 | 0.200 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2012 | 150 | 0.200 |
Why?
|
Metabolic Syndrome | 4 | 2008 | 141 | 0.200 |
Why?
|
Poultry | 6 | 2009 | 22 | 0.200 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 22 | 0.200 |
Why?
|
Hemorrhage | 1 | 2013 | 268 | 0.200 |
Why?
|
Mineral Fibers | 1 | 2011 | 2 | 0.200 |
Why?
|
Information Dissemination | 1 | 2012 | 103 | 0.200 |
Why?
|
Carrier Proteins | 4 | 2009 | 673 | 0.200 |
Why?
|
Europe | 7 | 2008 | 309 | 0.200 |
Why?
|
HLA-DR Antigens | 5 | 1991 | 61 | 0.200 |
Why?
|
Nuclear Family | 8 | 2002 | 92 | 0.200 |
Why?
|
Endothelial Cells | 1 | 2014 | 428 | 0.190 |
Why?
|
Homeodomain Proteins | 2 | 2010 | 536 | 0.190 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2013 | 236 | 0.190 |
Why?
|
Virulence | 6 | 2009 | 271 | 0.190 |
Why?
|
TCF Transcription Factors | 1 | 2010 | 23 | 0.190 |
Why?
|
Viral Proteins | 4 | 2012 | 300 | 0.190 |
Why?
|
Polysaccharides | 2 | 2011 | 89 | 0.190 |
Why?
|
Mice | 18 | 2013 | 11352 | 0.190 |
Why?
|
Asparaginase | 1 | 2010 | 35 | 0.190 |
Why?
|
Pregnancy in Diabetics | 1 | 2010 | 37 | 0.190 |
Why?
|
Coronaviridae Infections | 2 | 1990 | 7 | 0.190 |
Why?
|
Environmental Pollutants | 1 | 2011 | 51 | 0.190 |
Why?
|
Drug Hypersensitivity | 1 | 2010 | 37 | 0.190 |
Why?
|
Cat Diseases | 2 | 1990 | 20 | 0.190 |
Why?
|
Models, Molecular | 4 | 2012 | 1286 | 0.190 |
Why?
|
Alzheimer Disease | 3 | 2010 | 470 | 0.190 |
Why?
|
DNA-Binding Proteins | 5 | 2012 | 1208 | 0.190 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2013 | 90 | 0.180 |
Why?
|
Peritonitis | 2 | 1990 | 29 | 0.180 |
Why?
|
Receptors, AMPA | 1 | 2010 | 66 | 0.180 |
Why?
|
Environmental Exposure | 2 | 2011 | 296 | 0.180 |
Why?
|
Cluster Analysis | 5 | 2010 | 369 | 0.180 |
Why?
|
Neutralization Tests | 6 | 2009 | 77 | 0.180 |
Why?
|
Age Factors | 10 | 2014 | 1849 | 0.180 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 4 | 2010 | 45 | 0.180 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 479 | 0.180 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 7 | 1991 | 30 | 0.180 |
Why?
|
Infant, Newborn | 9 | 2013 | 2378 | 0.180 |
Why?
|
RNA-Binding Proteins | 3 | 2013 | 246 | 0.180 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 199 | 0.180 |
Why?
|
Birds | 5 | 2009 | 157 | 0.180 |
Why?
|
Chromosomes, Human | 4 | 2008 | 66 | 0.180 |
Why?
|
Texas | 6 | 2011 | 101 | 0.180 |
Why?
|
Receptor, Insulin | 5 | 2002 | 54 | 0.180 |
Why?
|
Inheritance Patterns | 3 | 2014 | 48 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2012 | 456 | 0.170 |
Why?
|
Precision Medicine | 1 | 2013 | 395 | 0.170 |
Why?
|
Biomedical Research | 1 | 2013 | 375 | 0.170 |
Why?
|
DNA, Satellite | 2 | 1995 | 18 | 0.170 |
Why?
|
Antigenic Variation | 4 | 2012 | 26 | 0.170 |
Why?
|
Folic Acid | 1 | 2009 | 60 | 0.170 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 1996 | 135 | 0.170 |
Why?
|
Nuclear Proteins | 4 | 2006 | 696 | 0.170 |
Why?
|
Poultry Diseases | 3 | 2009 | 13 | 0.170 |
Why?
|
RNA, Messenger | 6 | 2014 | 1981 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2013 | 6501 | 0.170 |
Why?
|
Complex Mixtures | 1 | 2008 | 6 | 0.170 |
Why?
|
Penetrance | 4 | 2013 | 44 | 0.160 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2012 | 276 | 0.160 |
Why?
|
Mexico | 4 | 2013 | 67 | 0.160 |
Why?
|
Cognition Disorders | 2 | 2010 | 236 | 0.160 |
Why?
|
Bayes Theorem | 3 | 2014 | 361 | 0.160 |
Why?
|
Viral Plaque Assay | 3 | 2011 | 19 | 0.160 |
Why?
|
Lipids | 1 | 2009 | 269 | 0.160 |
Why?
|
Birth Weight | 2 | 2013 | 145 | 0.160 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 104 | 0.160 |
Why?
|
North America | 4 | 2008 | 180 | 0.160 |
Why?
|
Global Health | 5 | 2012 | 193 | 0.160 |
Why?
|
Dogs | 5 | 2011 | 685 | 0.150 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2007 | 47 | 0.150 |
Why?
|
Trans-Activators | 1 | 2010 | 429 | 0.150 |
Why?
|
Bias | 2 | 2005 | 127 | 0.150 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2002 | 30 | 0.150 |
Why?
|
Spondylitis, Ankylosing | 1 | 2007 | 24 | 0.150 |
Why?
|
Apolipoproteins C | 1 | 1996 | 5 | 0.150 |
Why?
|
Heat-Shock Proteins | 2 | 2008 | 179 | 0.150 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 1997 | 62 | 0.150 |
Why?
|
Excitatory Amino Acid Transporter 3 | 1 | 2006 | 5 | 0.150 |
Why?
|
Genetics, Population | 6 | 2008 | 394 | 0.140 |
Why?
|
Chromosomes, Human, Pair 12 | 3 | 2005 | 65 | 0.140 |
Why?
|
Inflammation | 1 | 2012 | 920 | 0.140 |
Why?
|
Dementia | 3 | 1999 | 187 | 0.140 |
Why?
|
Biological Evolution | 4 | 2008 | 918 | 0.140 |
Why?
|
Viral Structural Proteins | 2 | 2007 | 19 | 0.140 |
Why?
|
Models, Biological | 4 | 2011 | 1749 | 0.140 |
Why?
|
Glycogen Synthase | 1 | 1996 | 22 | 0.140 |
Why?
|
Vaccines, Synthetic | 2 | 2011 | 55 | 0.140 |
Why?
|
Viral Core Proteins | 3 | 2013 | 27 | 0.140 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2008 | 302 | 0.140 |
Why?
|
Genomic Imprinting | 2 | 2010 | 33 | 0.140 |
Why?
|
Hypertriglyceridemia | 1 | 1996 | 67 | 0.140 |
Why?
|
RNA, Small Interfering | 3 | 2014 | 547 | 0.140 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2005 | 11 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2012 | 1313 | 0.140 |
Why?
|
Amantadine | 3 | 2007 | 18 | 0.140 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 1995 | 12 | 0.140 |
Why?
|
Amyloid | 1 | 1996 | 85 | 0.140 |
Why?
|
Asia | 2 | 2008 | 94 | 0.140 |
Why?
|
Geese | 2 | 2009 | 7 | 0.130 |
Why?
|
Sampling Studies | 4 | 2008 | 70 | 0.130 |
Why?
|
Esophageal and Gastric Varices | 1 | 1995 | 33 | 0.130 |
Why?
|
Genes, Tumor Suppressor | 1 | 1996 | 157 | 0.130 |
Why?
|
Promoter Regions, Genetic | 2 | 2011 | 937 | 0.130 |
Why?
|
Disease Models, Animal | 8 | 2013 | 2232 | 0.130 |
Why?
|
Survival Analysis | 2 | 2009 | 1538 | 0.130 |
Why?
|
Hypertension, Portal | 1 | 1995 | 47 | 0.130 |
Why?
|
Mothers | 2 | 2010 | 141 | 0.130 |
Why?
|
Genes, Regulator | 3 | 1989 | 65 | 0.130 |
Why?
|
Lung | 5 | 2014 | 1170 | 0.130 |
Why?
|
Lymphocytes | 1 | 2007 | 464 | 0.130 |
Why?
|
Sequence Alignment | 3 | 2009 | 351 | 0.130 |
Why?
|
Heterozygote | 5 | 2007 | 365 | 0.130 |
Why?
|
Glucose | 5 | 2012 | 638 | 0.130 |
Why?
|
Physicians | 2 | 2013 | 673 | 0.130 |
Why?
|
Monosaccharide Transport Proteins | 3 | 1990 | 73 | 0.130 |
Why?
|
Parents | 3 | 2012 | 272 | 0.130 |
Why?
|
Serologic Tests | 2 | 2008 | 41 | 0.130 |
Why?
|
Nedocromil | 1 | 2014 | 6 | 0.130 |
Why?
|
Survival Rate | 4 | 2013 | 1860 | 0.130 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 744 | 0.130 |
Why?
|
Russia | 3 | 2013 | 25 | 0.120 |
Why?
|
Mites | 1 | 2004 | 16 | 0.120 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 183 | 0.120 |
Why?
|
Forced Expiratory Volume | 1 | 2014 | 122 | 0.120 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2002 | 122 | 0.120 |
Why?
|
Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.120 |
Why?
|
Protein Binding | 4 | 2013 | 1456 | 0.120 |
Why?
|
Etoposide | 2 | 2011 | 196 | 0.120 |
Why?
|
Neoplasm Proteins | 3 | 2012 | 532 | 0.120 |
Why?
|
Phosphorylation | 3 | 2012 | 1106 | 0.120 |
Why?
|
Reference Values | 6 | 2009 | 674 | 0.120 |
Why?
|
Genetics, Behavioral | 1 | 1993 | 22 | 0.120 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 1673 | 0.120 |
Why?
|
Cloning, Molecular | 5 | 2011 | 646 | 0.120 |
Why?
|
Ice Cover | 1 | 2013 | 2 | 0.120 |
Why?
|
Mesothelioma | 2 | 2011 | 311 | 0.120 |
Why?
|
Protein Structure, Tertiary | 3 | 2011 | 736 | 0.120 |
Why?
|
Hemagglutinins | 2 | 2011 | 19 | 0.120 |
Why?
|
Anti-Asthmatic Agents | 1 | 2014 | 76 | 0.120 |
Why?
|
DNA Probes | 3 | 1990 | 77 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.120 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2008 | 43 | 0.120 |
Why?
|
Germany | 5 | 2007 | 72 | 0.120 |
Why?
|
Genetics, Medical | 2 | 2009 | 52 | 0.120 |
Why?
|
Proteinase Inhibitory Proteins, Secretory | 1 | 2013 | 2 | 0.120 |
Why?
|
Endoscopy | 1 | 1997 | 332 | 0.120 |
Why?
|
Inhibitory Concentration 50 | 3 | 2011 | 64 | 0.120 |
Why?
|
Clusterin | 1 | 2013 | 13 | 0.120 |
Why?
|
Chromosomes, Human, Pair 16 | 3 | 2013 | 79 | 0.110 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2013 | 66 | 0.110 |
Why?
|
Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1993 | 8 | 0.110 |
Why?
|
Sialic Acids | 2 | 2010 | 18 | 0.110 |
Why?
|
Climate Change | 1 | 2013 | 42 | 0.110 |
Why?
|
Tobacco Smoke Pollution | 1 | 2003 | 23 | 0.110 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2003 | 18 | 0.110 |
Why?
|
Cyclins | 1 | 2013 | 82 | 0.110 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2013 | 93 | 0.110 |
Why?
|
Bronchi | 2 | 2012 | 229 | 0.110 |
Why?
|
Age of Onset | 4 | 2007 | 310 | 0.110 |
Why?
|
Adiposity | 1 | 2013 | 70 | 0.110 |
Why?
|
SAP90-PSD95 Associated Proteins | 1 | 2012 | 2 | 0.110 |
Why?
|
Duodenitis | 1 | 1992 | 3 | 0.110 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1995 | 229 | 0.110 |
Why?
|
Siblings | 3 | 2014 | 111 | 0.110 |
Why?
|
Gallstones | 1 | 1992 | 14 | 0.110 |
Why?
|
Microsatellite Repeats | 4 | 2002 | 144 | 0.110 |
Why?
|
Cysteine Proteinase Inhibitors | 2 | 2003 | 53 | 0.110 |
Why?
|
Cytarabine | 1 | 2013 | 218 | 0.110 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2012 | 86 | 0.110 |
Why?
|
Cholesterol, HDL | 1 | 2003 | 165 | 0.110 |
Why?
|
International Cooperation | 1 | 2012 | 127 | 0.100 |
Why?
|
Apoptosis | 3 | 2013 | 1683 | 0.100 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2012 | 85 | 0.100 |
Why?
|
Fasting | 3 | 2013 | 161 | 0.100 |
Why?
|
Virus Shedding | 3 | 2011 | 26 | 0.100 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2004 | 206 | 0.100 |
Why?
|
Rimantadine | 2 | 2007 | 9 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2012 | 265 | 0.100 |
Why?
|
Frontal Lobe | 1 | 2012 | 130 | 0.100 |
Why?
|
C-Peptide | 3 | 2013 | 174 | 0.100 |
Why?
|
HN Protein | 1 | 2001 | 4 | 0.100 |
Why?
|
Genealogy and Heraldry | 1 | 2011 | 13 | 0.100 |
Why?
|
Virus Cultivation | 3 | 2011 | 20 | 0.100 |
Why?
|
Telomerase | 1 | 2011 | 55 | 0.100 |
Why?
|
Fibroblasts | 1 | 2014 | 729 | 0.100 |
Why?
|
Disease Transmission, Infectious | 1 | 2002 | 57 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 2012 | 163 | 0.100 |
Why?
|
Organoplatinum Compounds | 1 | 2011 | 94 | 0.100 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2011 | 63 | 0.100 |
Why?
|
Asia, Southeastern | 2 | 2008 | 16 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2012 | 92 | 0.100 |
Why?
|
Paclitaxel | 1 | 2012 | 460 | 0.100 |
Why?
|
Proteins | 3 | 2012 | 777 | 0.100 |
Why?
|
Viral Matrix Proteins | 2 | 2011 | 14 | 0.100 |
Why?
|
Gene-Environment Interaction | 1 | 2011 | 103 | 0.100 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.100 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 55 | 0.100 |
Why?
|
Consanguinity | 4 | 2005 | 73 | 0.100 |
Why?
|
Clinical Laboratory Techniques | 1 | 2011 | 73 | 0.100 |
Why?
|
Conserved Sequence | 3 | 2006 | 210 | 0.090 |
Why?
|
Virus Diseases | 1 | 2011 | 97 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2012 | 237 | 0.090 |
Why?
|
Platelet Aggregation | 1 | 1990 | 44 | 0.090 |
Why?
|
Respiratory Tract Infections | 1 | 2011 | 105 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2010 | 45 | 0.090 |
Why?
|
Evolution, Molecular | 3 | 2011 | 813 | 0.090 |
Why?
|
DNA Restriction Enzymes | 7 | 1991 | 98 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2011 | 315 | 0.090 |
Why?
|
Antigens, CD | 1 | 2012 | 458 | 0.090 |
Why?
|
Respiratory System | 3 | 2013 | 116 | 0.090 |
Why?
|
Treatment Outcome | 6 | 2014 | 7988 | 0.090 |
Why?
|
Antithrombin III | 1 | 1989 | 9 | 0.090 |
Why?
|
Fluorouracil | 1 | 2012 | 556 | 0.090 |
Why?
|
Introns | 3 | 2012 | 289 | 0.090 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 1989 | 27 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2011 | 692 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2011 | 1196 | 0.090 |
Why?
|
Logistic Models | 2 | 2011 | 1185 | 0.090 |
Why?
|
Isoantigens | 1 | 2009 | 66 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 860 | 0.090 |
Why?
|
Odds Ratio | 3 | 2013 | 678 | 0.090 |
Why?
|
Pregnancy Outcome | 2 | 2012 | 247 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 279 | 0.090 |
Why?
|
Matched-Pair Analysis | 3 | 2002 | 43 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2011 | 188 | 0.090 |
Why?
|
Genes, Dominant | 2 | 1996 | 117 | 0.090 |
Why?
|
Monoamine Oxidase | 1 | 2009 | 24 | 0.090 |
Why?
|
Acclimatization | 3 | 2003 | 76 | 0.090 |
Why?
|
Cold Temperature | 3 | 2003 | 157 | 0.090 |
Why?
|
Capital Financing | 1 | 1999 | 4 | 0.090 |
Why?
|
Family Health | 4 | 2003 | 162 | 0.090 |
Why?
|
Social Behavior Disorders | 1 | 2009 | 19 | 0.090 |
Why?
|
DNA Probes, HLA | 1 | 1988 | 2 | 0.090 |
Why?
|
Apolipoproteins B | 1 | 1988 | 38 | 0.090 |
Why?
|
Cell Nucleus | 1 | 2011 | 579 | 0.080 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 728 | 0.080 |
Why?
|
Cost of Illness | 4 | 2010 | 150 | 0.080 |
Why?
|
Protein Structure, Quaternary | 1 | 2009 | 99 | 0.080 |
Why?
|
Peptide Library | 1 | 2009 | 84 | 0.080 |
Why?
|
Finland | 2 | 2006 | 29 | 0.080 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2008 | 43 | 0.080 |
Why?
|
Gangliosides | 1 | 2008 | 10 | 0.080 |
Why?
|
Health Services | 1 | 1999 | 55 | 0.080 |
Why?
|
Somatomedins | 2 | 1988 | 28 | 0.080 |
Why?
|
Insulin-Like Growth Factor II | 2 | 1988 | 33 | 0.080 |
Why?
|
Brain | 2 | 2009 | 2216 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 1990 | 0.080 |
Why?
|
Drug Administration Schedule | 2 | 2009 | 916 | 0.080 |
Why?
|
Guillain-Barre Syndrome | 1 | 2008 | 16 | 0.080 |
Why?
|
Oceania | 1 | 2008 | 4 | 0.080 |
Why?
|
Spleen | 1 | 2009 | 430 | 0.080 |
Why?
|
Thailand | 2 | 2013 | 66 | 0.080 |
Why?
|
Monte Carlo Method | 3 | 1994 | 185 | 0.080 |
Why?
|
South America | 1 | 2008 | 29 | 0.080 |
Why?
|
Coronary Artery Disease | 1 | 2003 | 350 | 0.080 |
Why?
|
Neutrophils | 1 | 2009 | 307 | 0.080 |
Why?
|
tau Proteins | 1 | 2008 | 62 | 0.080 |
Why?
|
HMGB2 Protein | 1 | 2008 | 4 | 0.080 |
Why?
|
Recombination, Genetic | 5 | 2005 | 439 | 0.080 |
Why?
|
Christianity | 3 | 2001 | 36 | 0.080 |
Why?
|
Iodide Peroxidase | 2 | 1999 | 203 | 0.080 |
Why?
|
Nerve Degeneration | 1 | 2008 | 83 | 0.080 |
Why?
|
High Mobility Group Proteins | 1 | 2008 | 26 | 0.080 |
Why?
|
Brain Neoplasms | 1 | 2014 | 763 | 0.080 |
Why?
|
Population | 1 | 2008 | 35 | 0.080 |
Why?
|
Respite Care | 2 | 1997 | 9 | 0.080 |
Why?
|
Vitamin K Epoxide Reductases | 2 | 2013 | 16 | 0.080 |
Why?
|
Cytochrome P-450 CYP2C9 | 2 | 2013 | 21 | 0.080 |
Why?
|
Molecular Chaperones | 1 | 2008 | 111 | 0.080 |
Why?
|
Protein Isoforms | 1 | 2008 | 270 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2013 | 763 | 0.080 |
Why?
|
HeLa Cells | 1 | 2009 | 498 | 0.080 |
Why?
|
3' Untranslated Regions | 2 | 2012 | 92 | 0.080 |
Why?
|
Health Expenditures | 1 | 1999 | 86 | 0.080 |
Why?
|
Marriage | 1 | 1997 | 26 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2009 | 153 | 0.080 |
Why?
|
Child Language | 1 | 1997 | 5 | 0.080 |
Why?
|
HapMap Project | 2 | 2012 | 47 | 0.080 |
Why?
|
Age Distribution | 3 | 2009 | 204 | 0.080 |
Why?
|
Crystallography, X-Ray | 1 | 2009 | 485 | 0.080 |
Why?
|
Quality Control | 2 | 2014 | 117 | 0.080 |
Why?
|
Coronary Disease | 1 | 1988 | 261 | 0.080 |
Why?
|
Chromosome Segregation | 2 | 2004 | 32 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2007 | 216 | 0.080 |
Why?
|
Ubiquitin | 1 | 2008 | 93 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2012 | 999 | 0.080 |
Why?
|
Asbestos | 2 | 2011 | 22 | 0.080 |
Why?
|
Liver Transplantation | 1 | 1995 | 1267 | 0.070 |
Why?
|
DNA Methylation | 1 | 2012 | 628 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2012 | 3636 | 0.070 |
Why?
|
Lysine | 1 | 2008 | 147 | 0.070 |
Why?
|
Proinsulin | 1 | 2007 | 124 | 0.070 |
Why?
|
Protein Precursors | 1 | 2007 | 143 | 0.070 |
Why?
|
Financial Management | 1 | 1997 | 21 | 0.070 |
Why?
|
Military Medicine | 1 | 1997 | 20 | 0.070 |
Why?
|
Forecasting | 1 | 2008 | 304 | 0.070 |
Why?
|
Speech Disorders | 2 | 1993 | 18 | 0.070 |
Why?
|
Sex Characteristics | 2 | 2011 | 319 | 0.070 |
Why?
|
Injections, Intramuscular | 1 | 2006 | 62 | 0.070 |
Why?
|
Oligonucleotide Probes | 1 | 2006 | 39 | 0.070 |
Why?
|
Washington | 1 | 2006 | 48 | 0.070 |
Why?
|
Indians, North American | 2 | 2011 | 48 | 0.070 |
Why?
|
Virulence Factors | 1 | 2007 | 108 | 0.070 |
Why?
|
Prospective Studies | 3 | 2008 | 4210 | 0.070 |
Why?
|
Recurrence | 3 | 2012 | 1139 | 0.070 |
Why?
|
Virion | 2 | 1995 | 59 | 0.070 |
Why?
|
Microarray Analysis | 1 | 2006 | 96 | 0.070 |
Why?
|
HLA-DQ Antigens | 2 | 1991 | 52 | 0.070 |
Why?
|
DNA, Viral | 4 | 1999 | 265 | 0.070 |
Why?
|
Cross Reactions | 3 | 2012 | 106 | 0.070 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 252 | 0.070 |
Why?
|
Patient Admission | 1 | 1997 | 112 | 0.070 |
Why?
|
Neuregulin-1 | 1 | 2006 | 13 | 0.070 |
Why?
|
Transfection | 3 | 2011 | 896 | 0.070 |
Why?
|
Genetic Heterogeneity | 2 | 2001 | 62 | 0.070 |
Why?
|
Chicago | 2 | 2013 | 1379 | 0.070 |
Why?
|
Muscle, Skeletal | 2 | 2001 | 449 | 0.070 |
Why?
|
Crohn Disease | 1 | 1992 | 730 | 0.070 |
Why?
|
Upstream Stimulatory Factors | 1 | 2005 | 5 | 0.070 |
Why?
|
Endoscopy, Digestive System | 1 | 2006 | 65 | 0.070 |
Why?
|
Community Health Centers | 1 | 1997 | 113 | 0.070 |
Why?
|
Quality of Life | 1 | 2004 | 1583 | 0.070 |
Why?
|
Protein Folding | 1 | 2007 | 280 | 0.070 |
Why?
|
History, 20th Century | 2 | 2013 | 312 | 0.070 |
Why?
|
Macular Degeneration | 1 | 1996 | 59 | 0.070 |
Why?
|
Cognition | 1 | 2010 | 570 | 0.070 |
Why?
|
Genetic Vectors | 2 | 2011 | 439 | 0.070 |
Why?
|
Viral Vaccines | 2 | 2002 | 43 | 0.070 |
Why?
|
NADP | 2 | 2003 | 45 | 0.070 |
Why?
|
Mitochondria | 2 | 2013 | 535 | 0.070 |
Why?
|
Patient Compliance | 1 | 2006 | 227 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2012 | 1169 | 0.060 |
Why?
|
Web Browser | 1 | 2014 | 5 | 0.060 |
Why?
|
Muscles | 2 | 2012 | 194 | 0.060 |
Why?
|
DNA, Complementary | 2 | 1996 | 393 | 0.060 |
Why?
|
Hospitalization | 3 | 2013 | 848 | 0.060 |
Why?
|
Smoking | 1 | 2009 | 609 | 0.060 |
Why?
|
Genetic Association Studies | 2 | 2011 | 294 | 0.060 |
Why?
|
National Institute of Mental Health (U.S.) | 1 | 2004 | 22 | 0.060 |
Why?
|
Gastric Bypass | 1 | 2006 | 110 | 0.060 |
Why?
|
ErbB Receptors | 1 | 2007 | 485 | 0.060 |
Why?
|
Datasets as Topic | 1 | 2014 | 71 | 0.060 |
Why?
|
Mathematics | 4 | 1997 | 190 | 0.060 |
Why?
|
Gastrointestinal Diseases | 1 | 2006 | 146 | 0.060 |
Why?
|
Cell Growth Processes | 1 | 2014 | 83 | 0.060 |
Why?
|
Twins, Monozygotic | 1 | 2014 | 57 | 0.060 |
Why?
|
Prognosis | 3 | 2012 | 3674 | 0.060 |
Why?
|
Prevalence | 3 | 2010 | 1239 | 0.060 |
Why?
|
Diagnosis | 1 | 2013 | 14 | 0.060 |
Why?
|
Cell Count | 1 | 2014 | 195 | 0.060 |
Why?
|
Simvastatin | 1 | 2014 | 106 | 0.060 |
Why?
|
Pharmacokinetics | 1 | 2013 | 12 | 0.060 |
Why?
|
Swine Diseases | 1 | 2013 | 14 | 0.060 |
Why?
|
Host-Pathogen Interactions | 2 | 2013 | 231 | 0.060 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2004 | 203 | 0.060 |
Why?
|
Africa | 3 | 2007 | 98 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 1052 | 0.060 |
Why?
|
In Vitro Techniques | 2 | 2003 | 989 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2007 | 589 | 0.060 |
Why?
|
Language Development Disorders | 1 | 1993 | 24 | 0.060 |
Why?
|
Bacterial Proteins | 2 | 1991 | 864 | 0.060 |
Why?
|
RNA Isoforms | 1 | 2012 | 5 | 0.060 |
Why?
|
Meat | 1 | 2003 | 26 | 0.060 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 222 | 0.060 |
Why?
|
Clinical Protocols | 1 | 2013 | 156 | 0.060 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2012 | 43 | 0.060 |
Why?
|
Cell Adhesion | 1 | 2014 | 420 | 0.050 |
Why?
|
Psychotic Disorders | 1 | 2004 | 184 | 0.050 |
Why?
|
Protein Interaction Mapping | 1 | 2013 | 82 | 0.050 |
Why?
|
Thromboembolism | 1 | 2013 | 119 | 0.050 |
Why?
|
China | 4 | 2009 | 228 | 0.050 |
Why?
|
Receptors, Adiponectin | 1 | 2012 | 4 | 0.050 |
Why?
|
Protein Conformation | 2 | 2012 | 881 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2012 | 2501 | 0.050 |
Why?
|
Nucleocapsid Proteins | 3 | 2013 | 10 | 0.050 |
Why?
|
Resistin | 1 | 2012 | 14 | 0.050 |
Why?
|
Receptors, Leptin | 1 | 2012 | 32 | 0.050 |
Why?
|
History, 21st Century | 1 | 2013 | 175 | 0.050 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 1992 | 9 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2012 | 86 | 0.050 |
Why?
|
Students | 1 | 2013 | 147 | 0.050 |
Why?
|
Public Health | 1 | 2013 | 129 | 0.050 |
Why?
|
Organ Specificity | 1 | 2012 | 258 | 0.050 |
Why?
|
Metabolomics | 1 | 2012 | 68 | 0.050 |
Why?
|
Deoxyglucose | 1 | 2001 | 37 | 0.050 |
Why?
|
Thyroiditis, Autoimmune | 1 | 1991 | 16 | 0.050 |
Why?
|
Random Allocation | 1 | 2012 | 332 | 0.050 |
Why?
|
Acute Disease | 2 | 1997 | 826 | 0.050 |
Why?
|
Occupational Diseases | 1 | 2002 | 55 | 0.050 |
Why?
|
Osmolar Concentration | 1 | 2001 | 181 | 0.050 |
Why?
|
Electric Conductivity | 1 | 2001 | 144 | 0.050 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2011 | 27 | 0.050 |
Why?
|
Deoxycytidine Kinase | 1 | 2011 | 4 | 0.050 |
Why?
|
Cytogenetics | 1 | 2011 | 27 | 0.050 |
Why?
|
Intracellular Membranes | 1 | 2001 | 117 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2007 | 8475 | 0.050 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1991 | 47 | 0.050 |
Why?
|
Carcinogens, Environmental | 1 | 2011 | 5 | 0.050 |
Why?
|
Radiation Effects | 1 | 2011 | 28 | 0.050 |
Why?
|
Zeolites | 1 | 2011 | 4 | 0.050 |
Why?
|
Cocarcinogenesis | 1 | 2011 | 12 | 0.050 |
Why?
|
Daunorubicin | 1 | 2011 | 78 | 0.050 |
Why?
|
Gene Deletion | 2 | 2008 | 329 | 0.050 |
Why?
|
Cross-Cultural Comparison | 1 | 2001 | 34 | 0.050 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2000 | 25 | 0.050 |
Why?
|
Statistics, Nonparametric | 2 | 2007 | 307 | 0.050 |
Why?
|
Quail | 1 | 2000 | 8 | 0.050 |
Why?
|
Bird Diseases | 1 | 2000 | 7 | 0.050 |
Why?
|
Risk Assessment | 4 | 2014 | 2261 | 0.050 |
Why?
|
Micronucleus, Germline | 1 | 2010 | 3 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2012 | 256 | 0.050 |
Why?
|
Immunoglobulin E | 1 | 2001 | 144 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 879 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2014 | 482 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2011 | 155 | 0.050 |
Why?
|
Interpersonal Relations | 2 | 2004 | 170 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 beta | 2 | 2012 | 37 | 0.050 |
Why?
|
Nutritional Status | 1 | 2011 | 83 | 0.050 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2010 | 29 | 0.050 |
Why?
|
Oligopeptides | 1 | 2001 | 179 | 0.050 |
Why?
|
Internet | 1 | 2013 | 312 | 0.050 |
Why?
|
Proteomics | 1 | 2012 | 212 | 0.050 |
Why?
|
Plasmids | 1 | 2011 | 287 | 0.050 |
Why?
|
Receptors, Interleukin-4 | 1 | 2000 | 9 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2011 | 122 | 0.050 |
Why?
|
Adipocytes | 1 | 2001 | 155 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2010 | 131 | 0.050 |
Why?
|
Seroepidemiologic Studies | 3 | 2002 | 55 | 0.050 |
Why?
|
Specific Pathogen-Free Organisms | 2 | 1990 | 74 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 | 2 | 2012 | 63 | 0.050 |
Why?
|
Adipose Tissue | 1 | 2012 | 240 | 0.050 |
Why?
|
Calcium | 2 | 2003 | 1156 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2014 | 307 | 0.050 |
Why?
|
Perilipin-1 | 1 | 2009 | 7 | 0.050 |
Why?
|
Reye Syndrome | 1 | 1999 | 22 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 857 | 0.040 |
Why?
|
Cats | 2 | 1990 | 303 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2012 | 615 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2013 | 418 | 0.040 |
Why?
|
World Health Organization | 2 | 2012 | 103 | 0.040 |
Why?
|
Thermodynamics | 1 | 2010 | 309 | 0.040 |
Why?
|
Respiratory Tract Diseases | 1 | 1999 | 45 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2004 | 724 | 0.040 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 53 | 0.040 |
Why?
|
Neurons | 1 | 2008 | 1546 | 0.040 |
Why?
|
Administration, Intranasal | 1 | 1999 | 136 | 0.040 |
Why?
|
Selection, Genetic | 2 | 2005 | 502 | 0.040 |
Why?
|
Infant, Newborn, Diseases | 1 | 2010 | 111 | 0.040 |
Why?
|
Regression Analysis | 1 | 2011 | 596 | 0.040 |
Why?
|
Vietnam | 2 | 2009 | 14 | 0.040 |
Why?
|
Skin Tests | 2 | 2004 | 44 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 387 | 0.040 |
Why?
|
Environment | 4 | 2009 | 219 | 0.040 |
Why?
|
Genome | 1 | 2012 | 372 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 372 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 2 | 2007 | 143 | 0.040 |
Why?
|
Homozygote | 2 | 2005 | 200 | 0.040 |
Why?
|
Oligodeoxyribonucleotides | 2 | 1993 | 126 | 0.040 |
Why?
|
Patient Selection | 2 | 2009 | 685 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 322 | 0.040 |
Why?
|
Laparoscopy | 1 | 2006 | 754 | 0.040 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 397 | 0.040 |
Why?
|
Genetic Phenomena | 1 | 2008 | 6 | 0.040 |
Why?
|
Genetic Privacy | 1 | 2008 | 12 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2008 | 153 | 0.040 |
Why?
|
Isotopes | 1 | 2008 | 26 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2012 | 683 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 1996 | 348 | 0.040 |
Why?
|
Sequestosome-1 Protein | 2 | 2008 | 22 | 0.040 |
Why?
|
Mice, Inbred C57BL | 2 | 2003 | 3092 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2008 | 1621 | 0.040 |
Why?
|
Mass Spectrometry | 2 | 2009 | 188 | 0.040 |
Why?
|
Biomarkers | 2 | 2011 | 1718 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2008 | 379 | 0.040 |
Why?
|
Confidentiality | 1 | 2008 | 78 | 0.040 |
Why?
|
HIV-1 | 1 | 1999 | 163 | 0.040 |
Why?
|
Sex Distribution | 2 | 2009 | 173 | 0.040 |
Why?
|
Cricetinae | 2 | 1995 | 560 | 0.040 |
Why?
|
Medical Records | 1 | 2008 | 119 | 0.040 |
Why?
|
Diabetic Nephropathies | 1 | 2010 | 248 | 0.040 |
Why?
|
Receptors, Cytokine | 1 | 2007 | 28 | 0.040 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 429 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 1135 | 0.040 |
Why?
|
Contraindications | 2 | 2010 | 72 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2007 | 69 | 0.040 |
Why?
|
Endoscopes | 1 | 1997 | 9 | 0.040 |
Why?
|
United Kingdom | 2 | 2002 | 164 | 0.040 |
Why?
|
International Agencies | 1 | 2007 | 34 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2004 | 451 | 0.040 |
Why?
|
Adherens Junctions | 1 | 2007 | 34 | 0.040 |
Why?
|
Apolipoprotein C-III | 1 | 1996 | 8 | 0.040 |
Why?
|
Apolipoproteins A | 1 | 1996 | 11 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 1992 | 541 | 0.040 |
Why?
|
Haploidy | 1 | 1996 | 31 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 1961 | 0.040 |
Why?
|
Gene Library | 2 | 1996 | 130 | 0.040 |
Why?
|
Italy | 1 | 1996 | 106 | 0.040 |
Why?
|
Programming Languages | 1 | 2006 | 15 | 0.040 |
Why?
|
Trinucleotide Repeats | 1 | 1996 | 31 | 0.040 |
Why?
|
Sequence Tagged Sites | 1 | 1996 | 11 | 0.040 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1996 | 49 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 1987 | 177 | 0.040 |
Why?
|
Genetic Techniques | 2 | 2005 | 72 | 0.040 |
Why?
|
Data Collection | 2 | 1997 | 372 | 0.040 |
Why?
|
Apolipoprotein A-I | 1 | 1996 | 71 | 0.040 |
Why?
|
Islet Amyloid Polypeptide | 1 | 1996 | 25 | 0.040 |
Why?
|
Minisatellite Repeats | 2 | 2002 | 24 | 0.030 |
Why?
|
Severe Combined Immunodeficiency | 1 | 1995 | 17 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2008 | 296 | 0.030 |
Why?
|
Homeostasis | 2 | 2002 | 409 | 0.030 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2005 | 72 | 0.030 |
Why?
|
Biometry | 3 | 1997 | 66 | 0.030 |
Why?
|
Life Tables | 1 | 1995 | 48 | 0.030 |
Why?
|
Hybrid Cells | 1 | 1995 | 72 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2008 | 306 | 0.030 |
Why?
|
Mice, Obese | 1 | 1995 | 44 | 0.030 |
Why?
|
Drug Resistance, Microbial | 2 | 2001 | 72 | 0.030 |
Why?
|
Sulfonylurea Compounds | 1 | 1995 | 64 | 0.030 |
Why?
|
Luciferases | 1 | 2005 | 118 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2008 | 306 | 0.030 |
Why?
|
Informed Consent | 1 | 2008 | 266 | 0.030 |
Why?
|
Hepatocyte Nuclear Factor 4 | 2 | 2000 | 30 | 0.030 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1995 | 54 | 0.030 |
Why?
|
Jews | 1 | 1995 | 42 | 0.030 |
Why?
|
Binding Sites | 2 | 2013 | 1098 | 0.030 |
Why?
|
Statistics as Topic | 2 | 2001 | 238 | 0.030 |
Why?
|
Genes, Recessive | 1 | 1995 | 87 | 0.030 |
Why?
|
Hyperthyroxinemia | 1 | 1995 | 17 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2000 | 54 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2005 | 268 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1074 | 0.030 |
Why?
|
Costs and Cost Analysis | 2 | 1997 | 153 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 1995 | 286 | 0.030 |
Why?
|
Thimerosal | 1 | 2004 | 6 | 0.030 |
Why?
|
Preservatives, Pharmaceutical | 1 | 2004 | 10 | 0.030 |
Why?
|
Antigens, Dermatophagoides | 1 | 2004 | 11 | 0.030 |
Why?
|
Budesonide | 1 | 2014 | 45 | 0.030 |
Why?
|
Serum Albumin | 1 | 1995 | 130 | 0.030 |
Why?
|
Probability | 2 | 1986 | 355 | 0.030 |
Why?
|
Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2004 | 59 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2004 | 27 | 0.030 |
Why?
|
Testosterone | 1 | 2005 | 271 | 0.030 |
Why?
|
DNA Mutational Analysis | 2 | 2009 | 526 | 0.030 |
Why?
|
Antarctic Regions | 1 | 2013 | 5 | 0.030 |
Why?
|
Pacific Ocean | 1 | 2013 | 16 | 0.030 |
Why?
|
Health Records, Personal | 1 | 2013 | 11 | 0.030 |
Why?
|
Primates | 1 | 2005 | 151 | 0.030 |
Why?
|
Air | 1 | 2013 | 62 | 0.030 |
Why?
|
Serine Peptidase Inhibitor Kazal-Type 5 | 1 | 2013 | 2 | 0.030 |
Why?
|
Contact Tracing | 1 | 2013 | 29 | 0.030 |
Why?
|
Caribbean Region | 1 | 2013 | 20 | 0.030 |
Why?
|
Fear | 1 | 2004 | 78 | 0.030 |
Why?
|
Hyperlipoproteinemias | 1 | 2003 | 7 | 0.030 |
Why?
|
Seawater | 1 | 2013 | 43 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 285 | 0.030 |
Why?
|
bcl-2-Associated X Protein | 1 | 2013 | 47 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2008 | 1924 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2014 | 299 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 138 | 0.030 |
Why?
|
Scandinavian and Nordic Countries | 1 | 2002 | 10 | 0.030 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.030 |
Why?
|
Genomic Library | 1 | 1993 | 33 | 0.030 |
Why?
|
Chromosome Banding | 1 | 1993 | 74 | 0.030 |
Why?
|
Control Groups | 1 | 2002 | 15 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 1997 | 1685 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2004 | 157 | 0.030 |
Why?
|
Language Development | 1 | 1983 | 23 | 0.030 |
Why?
|
Glycogen Phosphorylase | 1 | 2012 | 6 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 273 | 0.030 |
Why?
|
Biotransformation | 1 | 2012 | 50 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2008 | 2818 | 0.030 |
Why?
|
Karyotyping | 1 | 1993 | 250 | 0.030 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2003 | 79 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 229 | 0.030 |
Why?
|
Computer Graphics | 1 | 2003 | 100 | 0.030 |
Why?
|
Cytosol | 1 | 1993 | 189 | 0.030 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2002 | 55 | 0.030 |
Why?
|
Ireland | 1 | 2002 | 9 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
Body Constitution | 1 | 2002 | 26 | 0.030 |
Why?
|
Haplorhini | 1 | 2002 | 81 | 0.030 |
Why?
|
Social Support | 1 | 2004 | 193 | 0.030 |
Why?
|
Incidence | 2 | 2006 | 1576 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2012 | 74 | 0.030 |
Why?
|
Bronchial Hyperreactivity | 2 | 2004 | 77 | 0.030 |
Why?
|
Uveal Neoplasms | 1 | 2011 | 11 | 0.030 |
Why?
|
Southwestern United States | 1 | 2011 | 8 | 0.030 |
Why?
|
Anxiety | 1 | 2004 | 287 | 0.030 |
Why?
|
Capecitabine | 1 | 2012 | 96 | 0.030 |
Why?
|
Protein Transport | 1 | 2013 | 411 | 0.030 |
Why?
|
Restriction Mapping | 2 | 1996 | 157 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2012 | 162 | 0.030 |
Why?
|
Virus Physiological Phenomena | 1 | 2011 | 8 | 0.030 |
Why?
|
Data Mining | 1 | 2011 | 42 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2011 | 48 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2011 | 51 | 0.030 |
Why?
|
Luminescent Measurements | 1 | 2011 | 57 | 0.020 |
Why?
|
DNA Replication | 1 | 2002 | 164 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2002 | 319 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2014 | 1204 | 0.020 |
Why?
|
Catheterization | 1 | 1992 | 232 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2014 | 1019 | 0.020 |
Why?
|
Adenosine Deaminase | 1 | 1991 | 20 | 0.020 |
Why?
|
Methylation | 1 | 2012 | 251 | 0.020 |
Why?
|
South Dakota | 1 | 2000 | 47 | 0.020 |
Why?
|
Genes, X-Linked | 1 | 2011 | 37 | 0.020 |
Why?
|
Immunization Programs | 1 | 2010 | 23 | 0.020 |
Why?
|
Remission Induction | 1 | 2012 | 722 | 0.020 |
Why?
|
Adenosine Diphosphate | 1 | 1990 | 55 | 0.020 |
Why?
|
Aging | 2 | 2008 | 691 | 0.020 |
Why?
|
Viruses | 1 | 2011 | 78 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1991 | 146 | 0.020 |
Why?
|
HIV Infections | 1 | 1999 | 772 | 0.020 |
Why?
|
Epinephrine | 1 | 1990 | 84 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2000 | 5 | 0.020 |
Why?
|
Cell Death | 1 | 2011 | 256 | 0.020 |
Why?
|
Emotions | 1 | 2004 | 341 | 0.020 |
Why?
|
Thrombin Time | 1 | 1989 | 4 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2011 | 217 | 0.020 |
Why?
|
Prothrombin Time | 1 | 1989 | 20 | 0.020 |
Why?
|
Partial Thromboplastin Time | 1 | 1989 | 18 | 0.020 |
Why?
|
Cerebellum | 1 | 2012 | 247 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 1989 | 28 | 0.020 |
Why?
|
Fibrinogen | 1 | 1989 | 56 | 0.020 |
Why?
|
Artifacts | 1 | 2001 | 244 | 0.020 |
Why?
|
Influenza A Virus, H5N2 Subtype | 1 | 2009 | 3 | 0.020 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2010 | 51 | 0.020 |
Why?
|
Nigeria | 1 | 2000 | 152 | 0.020 |
Why?
|
Platelet Count | 1 | 1989 | 92 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 98 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2009 | 94 | 0.020 |
Why?
|
Arginine | 1 | 2009 | 136 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2010 | 140 | 0.020 |
Why?
|
Primary Prevention | 1 | 2010 | 85 | 0.020 |
Why?
|
Cell Survival | 1 | 2012 | 969 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2001 | 165 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2008 | 1540 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2010 | 128 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2009 | 152 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 364 | 0.020 |
Why?
|
Apolipoproteins | 1 | 1989 | 38 | 0.020 |
Why?
|
Topography, Medical | 1 | 2008 | 4 | 0.020 |
Why?
|
Serotonin | 1 | 1990 | 218 | 0.020 |
Why?
|
Carbohydrate Metabolism | 1 | 1988 | 30 | 0.020 |
Why?
|
Gangliosidosis, GM1 | 1 | 2008 | 2 | 0.020 |
Why?
|
Porcine Reproductive and Respiratory Syndrome | 1 | 2008 | 2 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1988 | 245 | 0.020 |
Why?
|
Collagen | 1 | 1990 | 269 | 0.020 |
Why?
|
Midazolam | 1 | 2008 | 48 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2008 | 14 | 0.020 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2008 | 27 | 0.020 |
Why?
|
Epoxide Hydrolases | 1 | 2008 | 7 | 0.020 |
Why?
|
Glycolipids | 1 | 2008 | 29 | 0.020 |
Why?
|
Neurofibrillary Tangles | 1 | 2008 | 45 | 0.020 |
Why?
|
Color Perception | 1 | 1990 | 117 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 74 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2004 | 610 | 0.020 |
Why?
|
Cell Movement | 1 | 2012 | 758 | 0.020 |
Why?
|
Deubiquitinating Enzyme CYLD | 1 | 2008 | 2 | 0.020 |
Why?
|
TNF Receptor-Associated Factor 6 | 1 | 2008 | 6 | 0.020 |
Why?
|
Polyubiquitin | 1 | 2008 | 8 | 0.020 |
Why?
|
Sulfurtransferases | 1 | 1988 | 6 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2009 | 286 | 0.020 |
Why?
|
Receptor, trkA | 1 | 2008 | 14 | 0.020 |
Why?
|
Wisconsin | 1 | 2008 | 39 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 376 | 0.020 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 113 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2009 | 106 | 0.020 |
Why?
|
Solubility | 1 | 2008 | 177 | 0.020 |
Why?
|
Antibody Formation | 1 | 2008 | 171 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 2008 | 370 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 894 | 0.020 |
Why?
|
Cysteine Endopeptidases | 1 | 2008 | 87 | 0.020 |
Why?
|
Depressive Disorder | 1 | 1989 | 218 | 0.020 |
Why?
|
Peptides | 1 | 2011 | 639 | 0.020 |
Why?
|
Oxazines | 1 | 2007 | 13 | 0.020 |
Why?
|
Speech-Language Pathology | 1 | 1997 | 4 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2008 | 100 | 0.020 |
Why?
|
Xanthenes | 1 | 2007 | 23 | 0.020 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 23 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2008 | 236 | 0.020 |
Why?
|
Gene Amplification | 1 | 2007 | 131 | 0.020 |
Why?
|
Blood Platelets | 1 | 1988 | 149 | 0.020 |
Why?
|
Blotting, Western | 1 | 1999 | 782 | 0.020 |
Why?
|
Lipid Metabolism | 1 | 1988 | 196 | 0.020 |
Why?
|
Wnt Proteins | 1 | 2008 | 123 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2010 | 324 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1997 | 154 | 0.020 |
Why?
|
Galactose | 1 | 2007 | 32 | 0.020 |
Why?
|
Melanoma | 1 | 2011 | 454 | 0.020 |
Why?
|
Glycoconjugates | 1 | 2007 | 10 | 0.020 |
Why?
|
Transportation | 1 | 1997 | 18 | 0.020 |
Why?
|
DNA, Recombinant | 2 | 1996 | 67 | 0.020 |
Why?
|
Markov Chains | 1 | 1997 | 125 | 0.020 |
Why?
|
Fees and Charges | 1 | 1997 | 14 | 0.020 |
Why?
|
Oncogenes | 1 | 2007 | 88 | 0.020 |
Why?
|
Economic Competition | 1 | 1997 | 12 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1 | 2 | 1996 | 30 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 2 | 1996 | 34 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 1997 | 27 | 0.020 |
Why?
|
Rats | 2 | 2008 | 3990 | 0.020 |
Why?
|
Exercise | 1 | 2010 | 315 | 0.020 |
Why?
|
Health Care Costs | 1 | 1999 | 237 | 0.020 |
Why?
|
Income | 1 | 1997 | 75 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 1997 | 58 | 0.020 |
Why?
|
Kidney | 1 | 1993 | 1241 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2009 | 378 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 2 | 1996 | 80 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 1997 | 2600 | 0.020 |
Why?
|
Thyroxine | 2 | 1995 | 344 | 0.020 |
Why?
|
Nose | 1 | 2007 | 94 | 0.020 |
Why?
|
Databases, Nucleic Acid | 1 | 2006 | 41 | 0.020 |
Why?
|
Sequence Analysis | 1 | 2006 | 26 | 0.020 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2006 | 26 | 0.020 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 20 | 0.020 |
Why?
|
Denmark | 1 | 1995 | 15 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2010 | 864 | 0.020 |
Why?
|
Intestines | 1 | 2009 | 411 | 0.020 |
Why?
|
Pennsylvania | 1 | 1986 | 75 | 0.020 |
Why?
|
Biological Assay | 1 | 2006 | 78 | 0.020 |
Why?
|
Health Care Surveys | 1 | 1997 | 278 | 0.020 |
Why?
|
Trypsin | 1 | 2005 | 95 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 1997 | 174 | 0.020 |
Why?
|
Species Specificity | 2 | 2000 | 678 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2012 | 1458 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2010 | 521 | 0.020 |
Why?
|
Allantois | 1 | 1995 | 3 | 0.020 |
Why?
|
Rh-Hr Blood-Group System | 1 | 1985 | 6 | 0.020 |
Why?
|
Color Vision Defects | 1 | 1985 | 22 | 0.020 |
Why?
|
Codon | 1 | 1995 | 124 | 0.020 |
Why?
|
HLA-G Antigens | 1 | 2004 | 52 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2004 | 51 | 0.020 |
Why?
|
Adenosine Triphosphate | 2 | 1996 | 314 | 0.020 |
Why?
|
X Chromosome | 1 | 1985 | 152 | 0.020 |
Why?
|
Hemagglutination, Viral | 2 | 1984 | 4 | 0.020 |
Why?
|
Morbidity | 1 | 2004 | 148 | 0.020 |
Why?
|
International Classification of Diseases | 1 | 2004 | 69 | 0.020 |
Why?
|
Medicaid | 1 | 1997 | 217 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2005 | 182 | 0.020 |
Why?
|
Eggs | 1 | 1993 | 12 | 0.020 |
Why?
|
Speech Production Measurement | 1 | 1993 | 9 | 0.010 |
Why?
|
Dyslexia | 1 | 1993 | 11 | 0.010 |
Why?
|
Health Plan Implementation | 1 | 1994 | 56 | 0.010 |
Why?
|
Preoperative Care | 1 | 2006 | 394 | 0.010 |
Why?
|
Health Status | 1 | 2005 | 360 | 0.010 |
Why?
|
Lithium | 1 | 1983 | 59 | 0.010 |
Why?
|
Alcoholism | 1 | 1985 | 172 | 0.010 |
Why?
|
Dipeptides | 1 | 2003 | 46 | 0.010 |
Why?
|
Viral Envelope Proteins | 1 | 1993 | 94 | 0.010 |
Why?
|
Obesity, Morbid | 1 | 2006 | 225 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 416 | 0.010 |
Why?
|
Speech | 1 | 1993 | 84 | 0.010 |
Why?
|
Mood Disorders | 1 | 1983 | 81 | 0.010 |
Why?
|
Pneumonia | 1 | 2004 | 179 | 0.010 |
Why?
|
Cell Separation | 1 | 2003 | 196 | 0.010 |
Why?
|
Zoonoses | 1 | 2003 | 26 | 0.010 |
Why?
|
Drug Interactions | 1 | 2003 | 248 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2436 | 0.010 |
Why?
|
Rabbits | 1 | 1993 | 636 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2003 | 373 | 0.010 |
Why?
|
Infection Control | 1 | 2003 | 115 | 0.010 |
Why?
|
Epidemiologic Methods | 2 | 1989 | 59 | 0.010 |
Why?
|
Patient Discharge | 1 | 2004 | 300 | 0.010 |
Why?
|
Nucleotide Mapping | 1 | 1991 | 7 | 0.010 |
Why?
|
Hemagglutination Tests | 1 | 1991 | 11 | 0.010 |
Why?
|
Cross Infection | 1 | 2003 | 141 | 0.010 |
Why?
|
Body Weight | 1 | 2003 | 459 | 0.010 |
Why?
|
Iodides | 1 | 1991 | 18 | 0.010 |
Why?
|
Thyrotropin-Releasing Hormone | 1 | 1991 | 40 | 0.010 |
Why?
|
Length of Stay | 1 | 2004 | 700 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2002 | 80 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2003 | 271 | 0.010 |
Why?
|
Autoradiography | 1 | 1990 | 69 | 0.010 |
Why?
|
Untranslated Regions | 1 | 2000 | 19 | 0.010 |
Why?
|
Arizona | 1 | 2000 | 10 | 0.010 |
Why?
|
Bronchitis | 1 | 2000 | 7 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1990 | 274 | 0.010 |
Why?
|
Paraffin Embedding | 1 | 2000 | 78 | 0.010 |
Why?
|
Mass Vaccination | 1 | 2000 | 8 | 0.010 |
Why?
|
Administration, Oral | 1 | 2002 | 684 | 0.010 |
Why?
|
Neuropeptides | 1 | 2000 | 112 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2000 | 303 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2000 | 307 | 0.010 |
Why?
|
Thyrotropin | 1 | 1991 | 280 | 0.010 |
Why?
|
Carrier State | 1 | 2000 | 39 | 0.010 |
Why?
|
Muscle Proteins | 1 | 2000 | 132 | 0.010 |
Why?
|
Viral Nonstructural Proteins | 1 | 1999 | 37 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1991 | 270 | 0.010 |
Why?
|
Triiodothyronine | 1 | 1991 | 339 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1990 | 177 | 0.010 |
Why?
|
Goiter | 1 | 1999 | 43 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 1999 | 66 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1990 | 408 | 0.010 |
Why?
|
Viremia | 1 | 1999 | 54 | 0.010 |
Why?
|
Congenital Hypothyroidism | 1 | 1999 | 79 | 0.010 |
Why?
|
Intellectual Disability | 1 | 1999 | 186 | 0.010 |
Why?
|
Hypothyroidism | 1 | 1999 | 232 | 0.010 |
Why?
|
Lung Diseases, Interstitial | 1 | 2000 | 235 | 0.010 |
Why?
|
Biopsy | 1 | 2000 | 1161 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 1999 | 149 | 0.010 |
Why?
|
Receptors, Glucocorticoid | 1 | 1996 | 120 | 0.010 |
Why?
|
Triiodothyronine, Reverse | 1 | 1995 | 32 | 0.010 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 1995 | 35 | 0.010 |
Why?
|
Molecular Probes | 1 | 1995 | 35 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1995 | 290 | 0.010 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1984 | 18 | 0.010 |
Why?
|
Speech Therapy | 1 | 1983 | 8 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1995 | 1041 | 0.010 |
Why?
|
Ion Channel Gating | 1 | 1996 | 324 | 0.010 |
Why?
|
Photometry | 1 | 1990 | 14 | 0.010 |
Why?
|
Vision Tests | 1 | 1990 | 20 | 0.010 |
Why?
|
Antigens, Surface | 1 | 1980 | 101 | 0.010 |
Why?
|
Light | 1 | 1990 | 289 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1989 | 159 | 0.010 |
Why?
|
Arylsulfotransferase | 1 | 1988 | 4 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1990 | 912 | 0.000 |
Why?
|
Hospitals, Psychiatric | 1 | 1983 | 22 | 0.000 |
Why?
|
Epitopes | 1 | 1983 | 255 | 0.000 |
Why?
|
Erythrocytes | 1 | 1983 | 255 | 0.000 |
Why?
|